These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 37863339)
1. Influence of pulmonary rehabilitation on symptoms of anxiety and depression in interstitial lung disease: A systematic review of randomized controlled trials. Luu B; Gupta A; Fabiano N; Wong S; Fiedorowicz JG; Fidler L; Shorr R; Solmi M Respir Med; 2023; 219():107433. PubMed ID: 37863339 [TBL] [Abstract][Full Text] [Related]
2. Pulmonary rehabilitation for interstitial lung disease. Dowman L; Hill CJ; May A; Holland AE Cochrane Database Syst Rev; 2021 Feb; 2(2):CD006322. PubMed ID: 34559419 [TBL] [Abstract][Full Text] [Related]
3. Are idiopathic pulmonary fibrosis patients more anxious and depressive than patient's with other interstitial lung disease? Yalnız E; Polat G; Demirci F; Deniz S; Karadeniz G; Aydınlı E; Vayisoglu G; Ayrancı A Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(4):294-301. PubMed ID: 32476965 [TBL] [Abstract][Full Text] [Related]
4. Pulmonary rehabilitation for interstitial lung disease. Dowman L; Hill CJ; Holland AE Cochrane Database Syst Rev; 2014 Oct; (10):CD006322. PubMed ID: 25284270 [TBL] [Abstract][Full Text] [Related]
5. The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis. Green R; Baldwin M; Pooley N; Misso K; Mölken MPR; Patel N; Wijsenbeek MS Respir Res; 2024 Aug; 25(1):325. PubMed ID: 39192278 [TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
7. Local and Systemic Concentrations of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases. Vogt S; Trendelenburg M; Tamm M; Stolz D; Hostettler KE; Osthoff M Front Immunol; 2020; 11():562564. PubMed ID: 33101280 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Pollok J; van Agteren JE; Carson-Chahhoud KV Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012346. PubMed ID: 30566235 [TBL] [Abstract][Full Text] [Related]
11. Advances with pharmacotherapy for the treatment of interstitial lung disease. Comes A; Sgalla G; Perrotta A; Richeldi L Expert Opin Pharmacother; 2022 Mar; 23(4):483-495. PubMed ID: 34907821 [TBL] [Abstract][Full Text] [Related]
12. Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. Frank AL; Kreuter M; Schwarzkopf L Respir Med; 2019 Jun; 152():25-31. PubMed ID: 31128606 [TBL] [Abstract][Full Text] [Related]
13. Effect of home-based pulmonary rehabilitation on functional capacity in people with idiopathic pulmonary fibrosis-a systematic review protocol. Amin R; Vaishali K; Maiya GA; Mohapatra AK; Yadav UN; Parsekar SS Syst Rev; 2021 Nov; 10(1):297. PubMed ID: 34782011 [TBL] [Abstract][Full Text] [Related]
15. The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study. Janssen K; Rosielle D; Wang Q; Kim HJ Respir Res; 2020 Jan; 21(1):2. PubMed ID: 31900187 [TBL] [Abstract][Full Text] [Related]
16. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Saketkoo LA; Mittoo S; Huscher D; Khanna D; Dellaripa PF; Distler O; Flaherty KR; Frankel S; Oddis CV; Denton CP; Fischer A; Kowal-Bielecka OM; LeSage D; Merkel PA; Phillips K; Pittrow D; Swigris J; Antoniou K; Baughman RP; Castelino FV; Christmann RB; Christopher-Stine L; Collard HR; Cottin V; Danoff S; Highland KB; Hummers L; Shah AA; Kim DS; Lynch DA; Miller FW; Proudman SM; Richeldi L; Ryu JH; Sandorfi N; Sarver C; Wells AU; Strand V; Matteson EL; Brown KK; Seibold JR; Thorax; 2014 May; 69(5):428-36. PubMed ID: 24368713 [TBL] [Abstract][Full Text] [Related]
17. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Dowman LM; McDonald CF; Hill CJ; Lee AL; Barker K; Boote C; Glaspole I; Goh NSL; Southcott AM; Burge AT; Gillies R; Martin A; Holland AE Thorax; 2017 Jul; 72(7):610-619. PubMed ID: 28213592 [TBL] [Abstract][Full Text] [Related]
18. Ambulatory and short-burst oxygen for interstitial lung disease. Sharp C; Adamali H; Millar AB Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011716. PubMed ID: 27383922 [TBL] [Abstract][Full Text] [Related]
19. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M; Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830 [TBL] [Abstract][Full Text] [Related]
20. Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD). Ammous O; Feki W; Lotfi T; Khamis AM; Gosselink R; Rebai A; Kammoun S Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013778. PubMed ID: 36606682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]